



Bulletin from the Annual General Meeting in Qlife Holding AB on May 20th, 2020

Today, on 20th May 2020, the annual general meeting was held in Qlife Holding AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority of votes.

Resolution on adoption of accounts and allocation of the company's result

The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet. The annual general meeting also resolved in accordance with the proposal from the board of directors to allocate the company's result, meaning that no dividends are paid and that available funds of SEK 66 696 853 are carried forward.

Discharge from liability for the members of the board and the CEO

The annual general meeting resolved to discharge the board members and the CEO from liability for the financial year 2019.

Election and remuneration of the board of directors and auditors

The annual general meeting resolved in accordance with the proposal to re-elect Mette Gross, John Moll, Niklas Marschall and Thomas Warthoe as ordinary board members until the end of the next annual general meeting. Mette Gross was re-elected as chair of the board of directors.

Furthermore, the annual general meeting resolved in accordance with the proposal that remuneration to the board of directors shall be paid with SEK 200,400 to the chair of the board of directors and with SEK 66,800 to every other board member who is not employed by the company.

Finally, the annual general meeting resolved in accordance with the proposal to re-elect BDO Malmö as auditor and that remuneration to the auditor shall be paid according to customary norms and approved invoice. BDO Malmö has informed that the authorized public accountants Olof Andersson and Jörgen Lövgren will continue to be the auditors in charge.

Instruction and charter for the Nomination Committee

The annual general meeting resolved in accordance with the proposal from the Board that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall consist of four members representing the three largest shareholders as of the last calendar day in September 2020, as well as the Chair of the board of directors. Furthermore, an instruction and charter for the Nomination Committee was adopted.

Resolution on amendment of the Articles of Association

The annual general meeting resolved in accordance with the proposal from the board of directors to amend § 9 in the Swedish version of the Articles of Association, so that the provision, due to an anticipated upcoming legislative change, does not stipulate on which date the record date shall occur.

Resolution on authorization for the board of directors regarding issues

The annual general meeting resolved in accordance with the proposal from the board of directors to authorize the board of directors, at one or several occasions, during the time up until the next annual general meeting, with or without deviation from the shareholders' preferential rights, to resolve to issue new shares, convertibles and/or warrants. Issues may be made with or without provisions regarding payment in kind or through set-off or other provisions. The total number of shares that that may be issued pursuant to the authorization (alternatively be issued through conversion of warrants and/or exercise of convertibles) shall not exceed 2 793 610 shares, which corresponds to an aggregate dilution of approximately 20 percent calculated on the number of outstanding shares in the company. The purpose of the authorization is to enable the company to raise working capital, to execute acquisitions of companies or operating assets as well as to enable issues to industrial partners within the framework of partnerships and alliances. To the extent an issue is made with deviation from the shareholders' preferential rights, the issue should be made on market terms (subject to customary new issue discount, as applicable).

Helsingborg om May 20th, 2020

Qlife Holding AB

Mette Gross, Chair Qlife Holding AB

E-mail: mette.gross@lehdab.com

Tel. No.: +46 (0)73-517 85 25

About Qlife

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.

Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on [Egoo.health](https://egoo.health), [Qlifeholding.com](https://qlifeholding.com) or follow us on [LinkedIn](https://www.linkedin.com/company/qlife).